Publication | Closed Access

A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer

Breast OncologyMedicinePharmacologyCdk Inhibitor DinaciclibBreast CancerPharmacotherapyAnti-cancer AgentCancer TreatmentOncologyRadiation OncologyPhase 1Dose Expansion